Fever Clinical Trial
Official title:
Procalcitonin as a Marker of Serious Infection in Patients With Fever and a Central Venous Catheter
Procalcitonin (PCT) is one of many inflammatory markers which rises in response to
infection. Many studies have shown this marker to be more indicative of a patient's clinical
course in comparison to other inflammatory markers, such as Erythrocyte Sedimentation Rate
(ESR) and C reactive protein (CRP), when assessing a patient's risk for serious infection. A
particular population with potential for serious infection is that of the patient with fever
and a central line, most often secondary to an oncologic disease. These patients are often
neutropenic and unable to fight off infection, thereby rendering them extremely vulnerable
to rapid declines in clinical status. By identifying a level of procalcitonin which is
significant as a threshold for serious bacterial infection, the investigators can very early
on identify the sickest patients and those who could potentially have a worse clinical
course and/or outcome.
The primary study goal is to identify whether a level of procalcitonin exists above which
rates of bacteremia or serious bacterial infections in patients with fever and a central
line exist. The investigators will try to determine if levels of PCT correlate with
bacterial infection in line sepsis in the specific population of patients who most often
have a central line secondary to an oncologic process. The investigators proposed this
theory since peak values of PCT have been shown to be elevated in acute settings making it a
useful tool in this particular population.
A prospective study in which patients presenting to the Emergency Department (ED) with fever
and a central line will have procalcitonin levels checked, along with their CBC and blood
culture. Procalcitonin levels will be recorded and blood culture results will be followed to
see whether higher procalcitonin levels correlate with a greater risk of having a positive
blood culture.
A prospective study will be conducted on patients with fever and a central line who present
to the Emergency Department. Written informed consent will be obtained for each patient. We
will include all patients 18 years of age and younger and exclude patients who had received
antibiotics within the previous 24 hours of presenting to the ED as studies have shown that
PCT levels dramatically decrease with the institution of antibiotic therapy. Patients will
be identified on presentation to our ED with a chief complaint of "Fever and Central Venous
Catheter". Diagnosis of sepsis will be made by clinical findings (fever, chills, altered
mental status…) and confirmed by laboratory findings (leukocytosis or leucopenia with
neutropenia, and later positive blood cultures). Management of each individual patient was
determined by the pediatric emergency medicine physician in consult with a pediatric
hematologist-oncologist and, in required cases, by an intensivist.
On presentation to the ED, all patients will have a CBC with differential, blood culture
from the central line and procalcitonin levels drawn. All will receive empiric antibiotics
initiated with either Ceftriaxone (if the patients is clinically stable and non-neutropenic
defined as an Absolute Neutrophil Count (ANC)>1500 cells/microliter) or with Cefepime and
Gentamicin in the neutropenic or ill appearing patient.
Electronic medical records will be reviewed for patient demographics, medical and social
history and clinical presentation. Medical records during admission will be used to follow
the progression and hospital stay as well as the management used. Office records will be
used for post admission outcomes.
Levels of PCT will be determined using the Brahms Kryptor compact which required a minimum
of 200 microliters of plasma, serum or whole blood to run a PCT level and could detect a
level as low as <0.02ng/ml within 20-25 minutes. Levels reported as <0.05ng/ml are
considered not indicative of sepsis while levels >2 ng/ml are indicative of high sepsis
probability. Levels in between 0.05 and 2 suggest a repeat level be drawn after 24 hours.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03706599 -
Fever Infants and Therapeutic Education in Emergency Department
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Not yet recruiting |
NCT01782183 -
Thermographic Characteristics of Sore Throat by Thermographic Camera
|
N/A | |
Withdrawn |
NCT00800696 -
Preventive Oral Care
|
N/A | |
Completed |
NCT02689193 -
IDIS Project Work Package 2: Establishing a Biobank at ITM and Collaborating Centres
|
||
Completed |
NCT02212990 -
The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine
|
N/A | |
Completed |
NCT01869699 -
Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults
|
Phase 4 | |
Completed |
NCT01911143 -
A Retrospective, Blinded Validation of a Host-response Based Diagnostics
|
N/A | |
Completed |
NCT01194557 -
Introducing Rapid Diagnostic Tests Into the Private Health Sector
|
N/A | |
Completed |
NCT01559675 -
Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery
|
N/A | |
Completed |
NCT00940654 -
The Fever and Antipyretic in Critically Illness Evaluation Study
|
N/A | |
Completed |
NCT00969176 -
Pharmacokinetics, -Dynamics and Safety of Intravenous Paracetamol in Neonates
|
Phase 2/Phase 3 | |
Recruiting |
NCT00729976 -
Oral Versus Rectal Ibuprofen for Fever in Young Children - a Randomized Control Study.
|
Phase 4 | |
Recruiting |
NCT00389272 -
Adding a Second Drug for Febrile Children Treated With Acetaminophen
|
N/A | |
Completed |
NCT00257790 -
The Tobramycin Study
|
Phase 4 | |
Recruiting |
NCT05033613 -
Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease
|
||
Completed |
NCT02595827 -
Non-inferiority Trial of Conditional vs Universal Follow up for Children With Fever in Democratic Republic of Congo
|
Phase 3 | |
Recruiting |
NCT06061575 -
Comparison of the Efficacy of Paracetamol and Ibuprofen in the Management of Fever in Sepsis Patients
|
Phase 4 | |
Recruiting |
NCT06038617 -
Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children
|
Phase 4 |